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HIV-1 isolates harbouring an insertion in the β3–β4 loop of reverse transcriptase (RT) confer high-level resistance to nucleoside analogues.
We have identified a novel 5-amino-acid insertion (KGSNR amino acids 66–70) in a patient on prolonged nucleoside combination therapy
(didanosine and stavudine) and investigated which factors were responsible for its outgrowth. Remarkably, only small fold increases in drug
resistance to nucleoside analogues were observed compared to wild type. The insertion variant displayed a reduced replicative capacity in the
absence of inhibitor, but had a slight replicative advantage in the presence of zidovudine, didanosine or stavudine, resulting in the selection and
persistence of this insertion in vivo. Mathematical analyses of longitudinal samples indicated a 2% in vivo fitness advantage for the insertion
variant compared to the initial viral population. The novel RT insertion variant conferring low levels of resistance was able to evolve towards a
high-level resistant replication-competent variant.
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The human immunodeficiency virus type 1 (HIV-1) enzyme
reverse transcriptase (RT) is an important target for antire-
troviral treatment, due to its unique and essential role in the
virus life cycle (Arts and Wainberg, 1996). Nucleoside or
nucleotide reverse transcriptase inhibitors (NRTIs) compete
with the natural dNTPs for incorporation in the growing
proviral DNA chain (Boyer et al., 2001). Once incorporated,
further DNA synthesis is blocked, because NRTIs lack the 3′-
hydroxyl group essential for chain elongation. Unfortunately
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causing resistance are located around the nucleotide-binding
site. They confer resistance against NRTIs via two mechan-
isms: discrimination between the nucleotide analogue and its
natural counterpart (dNTP) or enhanced excision of the
incorporated nucleotide analogue (Huang et al., 1998; Selmi
et al., 2003). Continued treatment with NRTIs can lead to the
development of cross-resistance to the complete drug class.
Three pathways have been described that confer class
resistance. Accumulation of mutations associated with NRTI
cross-resistance, such as M41L, D67N, K70R, L210W,
T215Y/F and K219Q/E, is the most prevalent pathway
(Matsumi et al., 2003). Another pathway is referred to as
the Q151M pathway, in which the Q151M substitution is
selected, in combination with amino acid changes A62V,
V75I, F77L and F116Y (Deval et al., 2002; Kaushik et al.,
2000). The third pathway involves the selection of an
insertion between codons 68 and 69 or 69 and 70 and has
an estimated prevalence of less than 3% in therapy-failing
396 M.C.D.G. Huigen et al. / Virology 364 (2007) 395–406patients (Tamalet et al., 2000; Larder et al., 1999; Winters et
al., 1998; Ross et al., 1999; Sugiura et al., 1999). These
insertions are mostly dipeptides, mainly SS, SG or SA,Fig. 1. (A) Viral load, CD4+ count, treatment of patient M17001 and genotypic ana
points. The drug therapy is shown on top. At several time points during the treatment
was sequenced. For samples 4, 4A, 4B, 5 and 6 viral clones were generated and sequ
nucleotide sequences and corresponding amino acids 64 to 72 of HIV-1 RT are shown
15 nucleotides. AZT, zidovudine; 3TC, lamivudine; RTV, Ritonavir; d4T, stavudinealthough single amino acid as well as three to eleven amino
acid insertions have also been described (Sato et al., 2001;
Lobato et al., 2002; van der Hoek et al., 2005). Such insertionslyses. HIV-1 RNA copies and total CD4 counts were measured at several time
of patient M17001, as indicated by the black arrows, the plasma viral population
enced as well. (B) Nucleotide sequence of the 5-amino-acid insertion in RT. The
for sample 4 and sample 5. The insertion is an exact duplication of the previous
; ddI, didanosine; SAQ, Saquinavir.
Fig. 2. Competition experiments between S4C18 and S5C22 (insert). S4C18
(sample 4 clone, without insertion) was competed with S5C22 (sample 5 clone,
with insertion) in PBMC for 5 passages. At several time points the percentage of
both viruses in the culture was determined by sequencing as described in the
Materials and methods section. Shown are two independent experiments that
were started at a 50:50 (A) or 75:25 ratio (B) based on TCID50. The variability
is indicated by error bars representing the standard error of the mean (SEM).
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HIV-1 RT, which plays a key role in the functioning of the
polymerase by positioning the template and incoming
nucleotide (Fisher et al., 2003). Genotypic analysis indicates
that these insertions are usually duplications of prior
codons, supporting the general opinion that generation of
insertions is explained by slippage of RT at a pausing site
(Harrison et al., 1998). The selection of insertions usually
occurs during treatment with at least one thymidine
analogue (d4T and/or AZT). They generally appear in the
background of specific thymidine associated mutations
(TAMs), such as the M41L, K70R, L210W and T215Y/F
changes and are highly associated with A62V, D67E/G and
T69S substitutions (Ross et al., 1999; Lukashov et al.,
2001; Moyle et al., 2000). When accompanied by (a part
of) these mutations the insertion complex invariably causes
high-level resistance to all approved nucleoside analogues.
The precise mechanism through which these insertions
cause resistance is not clear. Although the insertion is able
to increase the discrimination of a nucleotide analogue, the
major mechanism of resistance for the insertion complex
appears to be the increased excision of NRTIs from their
terminated primer (Meyer et al., 2003; Boyer et al., 2002; Mas
et al., 2000).
We have identified an HIV-1 variant harbouring a stable
novel 5-amino-acid insertion in the fingers domain of RT in a
patient failing on nucleoside combination therapy. In this study
we have analyzed which factors drive the selection of this novel
insertion variant.
Results
Genotypic analysis
Longitudinal plasma samples of patient M17001 were
genotypically analyzed as shown in Fig. 1. At 263 weeks
after start of highly active antiretroviral therapy (HAART) the
viral population sequence (sample 5) revealed a very large,
unique insertion of 15 nucleotides around codon 66 in RT.
These 15 nucleotides encoded for amino acids KGSNR; an
exact duplication of amino acids 66 to 70 (Fig. 1B). This 5-
amino-acid insertion was selected in the background of the
D67G, K70R, V118I, K219Q and the unusual T69N and
T215I amino acid changes. Several other mutations that are
not associated with an insertion in the fingers domain of RT
were present in the viral background as well (Fig. 1).
Selection of the insertion in RT did not coincide with
substitutions in the C-terminal part of RT and/or protease
(data not shown).
During sustained treatment with stavudine (d4T) and
didanosine (ddI) the T215I substitution evolved towards a
mixture of phenylalanine and threonine, whereas the 5-amino-
acid insertion remained stably present in the viral population
(Fig. 1). In this study we wanted to investigate which factor(s) is
(are) driving the selection of this unique insertion, and therefore
we determined its effect on replication capacity and drug
susceptibility.Replication capacity of the novel insertion variant
To investigate if the selection of the 5-amino-acid insertion
variant is caused by an increase in replication capacity a
recombinant virus clone was generated, which was representa-
tive of the viral population (sample 5 clone 22; S5C22 (insert)).
For comparison a representative recombinant virus clone of
sample 4 was generated (sample 4 clone 18; S4C18, Fig. 1).
Replication competition experiments demonstrated a nega-
tive effect on replication capacity, since S4C18 completely
replaced the insertion-containing virus S5C22 (insert) clone
(Fig. 2). Moreover, in vitro evolution experiments demon-
strated that the 5-amino-acid insertion was deleted after 65 days
when the virus clone S5C22 (insert) was cultured in PBMC in
the absence of RT inhibitors, while all other amino acid
changes remained stably present (data not shown). Thus, in the
absence of drug pressure the replication capacity of the
insertion variant is decreased compared to its predecessor,
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novel insertion.
Drug susceptibility analysis
To determine the impact of this novel insert variant on drug
susceptibility the recombinant virus clones S5C22 (insert) and
S4C18 were phenotypically analyzed. Results of at least
duplicate experiments are shown in Table 1B. To our surprise,
no high-level resistance for S5C22 (insert) could be determined
for the three NRTIs tested. The moderate reductions in
susceptibility to AZT, d4T and ddI were respectively 9-, 3-,
and 2-fold.
Our results were confirmed by the phenotypic assays from
Monogram Biosciences (formerly ViroLogic; PhenoSense
assay) and VIRalliance (PhenoScript assay). In these assays
no high-level resistance could be observed for S5C22 (insert) as
well (data not shown).
A small increase in resistance was observed for S5C22
(insert) compared to S4C18 for AZT in PBMC (9-fold
compared to 3-fold), whereas no difference could be measured
for d4T and ddI. However, small increases in drug resistance in
PBMC were measured when we determined the viral replication
capacity under drug pressure (Fig. 3). The level of virusTable 1
Drug resistance analyses for several viral HIV-1 clones derived from patient M1700
(A)
Consensus B 66 K 67 D 68 S 69 T 70 K
S4C18 G N R
S5C22 G N R K
S5C22-R70A G N R K
S6C3 G N R K
S6C4 G D N R K
S6C10 G D N R K
(B)
PBMC AZT ddI
IC50 (nM)
(mean±SEM)
Fold increase
in IC50
IC50 (
(mean±
HXB2 (wild type) 23±9 1894±
S4C18 70±24 3 2729±
S5C22 209±100 9 3347±
S6C3 288±230 13 5297±
S6C4 2592±1469 113 4296±
S6C10 2030±409 88 3970±
(C)
MT2 cells AZT
IC50 (nM) (mean±SEM) Fold increas
S5C22 2321±807
S5C22-R70A 1179±340 0.5
Five representative viral clones from patient M17001 were analyzed for their suscep
represents a viral clone without the insertion and sample 5 clone 22 (S5C22) contains
in the patient. To determine the mechanism of resistance the second arginine at posi
S5C22-R70A.
Shown are relevant amino acid changes (A) the mean IC50 values compared to a wild ty
AZT; zidovudine, d4T; stavudine, ddI; didanosine.replication in the presence of serial dilutions of either d4T, ddI
or AZT was assessed and for all drugs tested, an increased
replication in the presence of inhibitor was observed for S5C22
(insert) as compared to S4C18. This means that at the higher
drug concentrations the insertion variant (S5C22 (insert))
confers a higher replication capacity than the non-insertion
variant (S4C18), indicating a small replicative advantage for the
insertion-variant under d4T, ddI or AZT pressure in PBMC.
Modeling of the 5-amino-acid insertion in RT and its putative
mechanism of resistance
To obtain possible insights into the three-dimensional
structure of this large insertion and its corresponding mechan-
ism of resistance, a 3D model was generated (Fig. 4). Because
of the surface location of R70, the 5-residue insertion can be
accommodated relatively easily in the RT structure. The
minimized model gave indications of binding of the duplicated
R70 to the triphosphate moiety of the substrate (dTTP) and by
extrapolation, to the inhibitor (AZT-TP) and also to the ATP
used for excision of the blocked primer, in the binding mode
modeled in previous reports (Boyer et al., 2001; Chamberlain et
al., 2002). To determine if the second positively charged
arginine is indeed responsible for the increase in resistance, a1
118 V 215 T 219 K
I Q
G S N R I I Q
G S N A I I Q
G S N R I Q
G S N R I F Q
G S N R I Q
d4T
nM)
SEM)
Fold increase
in IC50
IC50 (nM)
(mean±SEM)
Fold increase
in IC50
451 223±73
795 1 739±192 3
487 2 719±99 3
2285 3 702±390 3
591 2 1783±1351 8
783 2 953±112 4
e in IC50
tibility for several reverse transcriptase inhibitors. Sample 4 clone 18 (S4C18)
the novel 5-aa insertion. Sample 6 clones correspond to the evolved virus variant
tion 70 (of the insert) was replaced by a neutral alanine, resulting in virus clone
pe reference virus (HXB2) in PBMC (B) or compared to S5C22 in MT2 cells (C).
Fig. 3. Replication capacity under drug pressure. The replication capacity of
S4C18 and S5C22 was determined under a serial dilution of either d4T (A), ddI
(B) or AZT(C). The amount of viral production in PBMC after 7 days, measured
by P24 ELISAwas plotted in a graph. Representative experiments are shown. In
each experiment the virus production was measured in triplicate; the variability
is indicated by error bars representing the standard error of the mean (SEM).
399M.C.D.G. Huigen et al. / Virology 364 (2007) 395–406site-directed mutant was generated in which the arginine was
replaced by an uncharged alanine (A) (S5C22-R70A; Table
1A). It was demonstrated that the replacement of the second
arginine by an alanine indeed resulted in a two-fold decrease in
IC50 for AZT (Table 1C).In vivo fitness and evolution of the insertion variant
To determine the fitness advantage of this novel insertion in
vivo, viral clones were generated as described previously and
genotypically analyzed to determine the percentage of virus in
the population that contains the insertion. In sample 4A only 1
out of the 20 clones (5%) contained the insertion, while sample
4B revealed that 20% of the viral population harboured the
insertion (4/20 clones). These clonal frequencies in combination
with the viral load over time were used to estimate that the in
vivo fitness advantage of the insertion mutant was 2.1%
(±0.6%).
We have shown that the selection of this insertion is driven by
a small increase in drug resistance. However, since the effect on
drug resistance was rather small we investigated if the virus was
able to evolve towards a better replicating and/or more resistant
variant under continued drug pressure in the patient. Long-
itudinal plasma samples from patient M17001, who remained on
the same therapy, were sequenced (Fig. 1).We demonstrated that
the KGSNR insertion remains stably present in the patient.
However, continuous viral evolution was observed, as indicated
by the acquisition of a serine-to-aspartate substitution at position
68 (S68D). This double transition amino acid change was stably
selected whereas the isoleucine (I) at codon 215 was replaced by
a mixture of phenylalanine (F) and the wild type threonine (T).
Recombinant virus clones representing these different viral
variants were generated from sample 6 (S6C3, S6C4 and
S6C10) and their susceptibility to AZT, d4T and ddI was
determined in PBMC (Table 1). As shown in Table 1B the
evolved insertion variants conferred high-level resistance
against both AZT and d4T. Moreover, replication competition
experiments using S6C4 and S5C22 demonstrated a replicative
advantage for S6C4, which indicates that the replication
capacity is increased as well (Fig. 5). Analysis of the reverse
transcriptase activity of the virus clone before selection of the
insertion (S4C18), the initial insertion variant (S5C22) and the
evolved insertion variant (S6C4) revealed the same trend as
described for replication capacity (Fig. 6).
Discussion
In this study we investigated the evolution of a novel
insertion in RT (KGSNR; duplication of amino acids 66–70)
that was selected in a patient on prolonged non-suppressive
nucleoside combination therapy in the background of multiple
RT mutations (D67G, T69N, K70R, V118I, T215I and K219Q).
We studied longitudinal samples of this patient and investigated
recombinant virus clones for their effect on replication and drug
susceptibility.
The insertion variant displayed a reduced replicative capacity
in the absence of inhibitor, but had a slight replicative advantage
in the presence of didanosine or stavudine, resulting in the
selection and persistence of this insertion in vivo. The insertion
variant was able to evolve towards a replication-competent,
high-level resistant variant under continued drug pressure.
Although there is still debate about the effect of insertions on
processivity, the general opinion holds that insertions in the
400 M.C.D.G. Huigen et al. / Virology 364 (2007) 395–406
Fig. 5. Competition experiments between S5C22 and S6C4. S5C22 (sample 5
clone, with insertion) was competed with S6C4 (sample 6 clone 4, in vivo
evolved insertion variant) in Sup-T1 cells for two passages. At several time
points the ratio of the two viruses in the culture was determined by sequencing.
Results are two independent experiments that started with either a 50:50 ratio
(A) or a 75:25 ratio (B) based on TCID50. The variability is indicated by error
bars representing the standard error of the mean (SEM).
Fig. 6. Reverse transcriptase activity. The reverse transcriptase activity was
determined using a colorimetric RT activity kit as described in the Materials and
methods section. S4C18 (sample 4 clone, without insertion), S5C22 (sample 5
clone, with insertion) and S6C4 (sample 6 clone, evolved insertion variant) were
analyzed. HXB2 (wild type reference strain) and 184T (reference strain with
single M184T change) were used as a control for a respectively wild type or
severely decreased reverse transcriptase activity. As input 20 ng p24 was used
for each virus clone. The variability is indicated by error bars representing the
standard error of the mean (SEM).
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defect in the efficiency of nucleotide incorporation or proces-
sivity (Boyer et al., 1999, 2002; Sato et al., 2001; Mas et al.,
2000; Kew et al., 1998; Lukashov et al., 2001). In this study, we
described a novel 5-amino-acid (KGSNR) insertion that resulted
in a reduction in viral replication capacity and RTactivity, which
is in agreement with previously described insertions.
A striking difference however was the low level of resistance
that was observed for this new variant. All other patient-derivedFig. 4. Modeling of the 5-amino-acid insertion in reverse transcriptase. (A) Cartoon re
DNA generated from 1RTD pdb coordinates. The p51 subunit is colored silver, the p6
yellow respectively. The 5-amino-acid insertion (KGSNR) in the fingers domain of p
with resistance to thymidine analogues (M41, T215 andW210) is shown as magenta s
5-amino-acid insertion in the fingers domain of p66 generated from modeling studies.
insertion is highlighted in magenta; the template:primer strands in green and yellow r
and R70 of the insertion and the dTTP substrate are illustrated as ball and stick repr
shown in magenta. Ionic and/or hydrogen-bonding interactions including that propo
yellow lines.virus variants harbouring an insertion in the β3–β4 loop that
have been described demonstrated high-level resistance to all
nucleoside analogues (Eggink et al., 2007; Boyer et al., 1999,
2002; Sato et al., 2001; Mas et al., 2000; Kew et al., 1998;
Lukashov et al., 2001). Only in vitro engineered (serine)
insertions without additional (resistance) mutations in reverse
transcriptase were not able to decrease nucleoside analogue
susceptibility (Quinones-Mateu et al., 2002). Our results imply
that in vivo selected insertions in the β3–β4 loop of RT are not
high-level resistant by definition.
Modeling studies and resistance assays revealed that the
additional positive charge by the (second) arginine was
responsible for a 2-fold increase in AZT resistance. The effects
observed are, however, rather small and thus deciding which
triphosphate binding may be affected is not straightforward,
particularly given the flexibility of this region. Nevertheless, the
second arginine at position 70 does at least appear partly
responsible for the observed resistance against AZT.
We may be able to explain the low resistance profile of our
insertion variant based on the absence of accompanying
resistance mutations. Namely, considering all published
sequences of in vivo selected RT insertion variants, we noticed
that our unusual KGSNR insert variant did not contain the
“usual” insertion-accompanying substitutions. Most insertion
variants harbour a T69S and T215Y change and are highly
associated with the M41L, L210W, A62V and D67E/Gpresentation of the overall architecture of HIV-1 RTwith bound template: primer
6 subunit is blue, while the template:primer DNA strands are shown in green and
66 is illustrated in magenta. The location of amino acids commonly associated
pheres. (B) Cartoon illustration of the proposed interaction of residues within the
The main chains are shown in schematic form colored in blue; the 5-amino-acid
espectively. The catalytic triad (D110, D185 and D186) along with residues K65
esentations. A magnesium ion and the location of residues T215 and W210 are
sed for the duplicated R70 with the substrate triphosphate are shown as broken
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2000; Kew et al., 1998; Lukashov et al., 2001). Remarkably, of
all these substitutions only the latter one is present in our
insertion variant. Unfortunately, the exact function of this
specific amino acid in insertion-containing variants is unknown,
despite the fact that almost all described RT insertions are
accompanied by a substitution at this particular codon. With
respect to the M41L and T215Y, which are lacking in our
insertion-variant, data have shown that they play a critical role
by increasing the rate of ATP-dependent primer unblocking and
thereby resistance (Boyer et al., 2002). Furthermore, also
selection of the flanking T69S (in our variant: T69N) is
suggested to increase polymerase activity and processivity
(Boyer et al., 1999). Considering that the novel insertion variant
in this study did not harbour any of these changes, the obtained
low resistance profile seems plausible.
Interestingly, when our variant evolved towards a high-level
resistant virus, still none of these known substitutions (e.g.,
M41L, T215Y, L210W, T69S) was selected. Apparently,
selection of other “unknown” mutations in the viral reverse
transcriptase enzyme can also increase the resistance profile of
an insertion variant. This was also demonstrated by Bulgheroni
et al. who have described two unusual patient-derived RT
insertion variants, that were lacking most classical mutations as
well, but conferred high-level resistance (Bulgheroni et al.,
2004). We therefore hypothesize that the specific genetic
background and the nature of the insertion itself will impact the
evolutionary pathway to improve fitness. When our variant
evolved towards a high level of resistance two amino acid
changes were consistently observed. A mixture of 215F/T was
selected, but a comparison of two clonal isolates with and
without this change, demonstrated that that this mutation did not
seem to play a critical role in resistance. The acquisition of the
serine-to-aspartate substitution at codon 68 did increase the
resistance to AZT towards very high levels. This S68D change
is the result of two transitions and is hardly ever observed before
in (un)treated HIV-1 subtype B isolates (hivdb.stanford.edu). To
our knowledge, this amino acid change has been described once
in a Korean HIV-1 subtype B isolate, which interestingly
harboured the T69N as well (Cho et al., 2002).
Several studies have demonstrated that the initially impaired
replication capacity of RT insertion variant can be (partly)
compensated. For instance, the sequence of the insertion has
been shown to be responsible for subtle differences in the rates
of excision and replication capacity. An SS insertion has been
described that evolved towards an SG insertion that revealed a
higher excision rate and an advantage in in vitro polymerase
assays (Boyer et al., 1999, 2002; Quinones-Mateu et al., 2002).
Furthermore, the background of the insertion virus has been
shown to be important as well. Previous studies demonstrated
that recombinant viruses containing a clinical RT insertion
variant revealed a higher replication capacity when compared to
a site-directed mutant containing the same insertion in a wild
type backbone(Prado et al., 2004; Quinones-Mateu et al., 2002,
indicating that the presence of particular amino acids (at
unknown positions) may influence the replication capacity of an
insert in RT. Apparently, HIV-1 is capable of (partly)compensating for the insertion by the selection of mutations,
which not necessarily have to be the “known” resistance
mutations. Also in our study, we have demonstrated that low
level resistant insertion variant with a low replication capacity is
able to evolve towards a high-level resistant replication-
competent variant by selecting novel mutations, such as
S68D, in reverse transcriptase.
It could be questioned that the continuous pressure of
protease inhibitors (also) played a role in the selection of this
novel insertion. However, clonal sequencing has demonstrated
that the insertion is not co-selected with a protease inhibitor
resistance mutation, but has a selective fitness advantage on its
own. Also, although we have sequenced the complete reverse
transcriptase and protease genes of sequential plasma samples,
we cannot exclude the influence of putative mutations in other
genes. But, we believe that it is unlikely that the insertion is co-
selected with other mutations because of its dramatic influence
on replication capacity. Furthermore, mutations in reverse
transcriptase can also be selected when they confer cytotoxic T
lymphocyte (CTL) escape (Goulder et al., 1997). Again, this
appears unlikely since the insertion does not disrupt a known
CTL epitope in RT according to the Los Alamos database
(http://hiv-web.lanl.gov).
In conclusion, we have investigated the factors driving the
selection of a novel KGSNR insertion at position 66 in RT. It
was demonstrated that the insertion resulted in a decrease in
viral replication capacity, but showed a small fitness advantage
at relatively high drug concentrations (d4T, ddI and AZT).
Under sustained drug pressure the virus was able to evolve
towards a high-level resistant variant with a higher replication
capacity.
Materials and methods
Cells
Peripheral blood mononuclear cells (PBMC) were isolated
from blood of five HIV-negative human donors (Sanquin
Blood bank, Utrecht, The Netherlands) by means of Ficoll-
Paque (Amersham Biosiences, Roosendaal, The Netherlands)
gradient centrifugation. Aliquots of the pooled cells were
frozen at −130 °C in RPMI 1640 medium with L-glutamine
(Cambrex, Verviers, Belgium), supplemented with 20% heat-
inactivated fetal calf serum (FCS, Invitrogen), 10% dimethyl
sulfoxide (DMSO, Merck, Darmstadt, Germany) and 10 μg/ml
gentamicin (Invitrogen). Three to 4 days before use, the cells
were cultured in RPMI 1640 medium, supplemented with L-
glutamine, 10% FCS and 10 μg/ml gentamicin and stimulated
with 2 μg/ml phytohemagglutinin (PHA, Sigma, St. Louis,
USA).
MT-2 cells and Sup-T1 cells were cultured in RPMI 1640
medium, supplemented with L-glutamine, 10% FCS and 10 μg/
ml gentamicin and passaged twice a week. 293 T cells were
maintained in Dulbecco's modified Eagle's medium (DMEM,
BioWhittaker, Verviers, Belgium) supplemented with 10% FCS
and 10 μg/ml gentamicin. All cells were maintained at 37 °C
and 5% CO2.
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Patient M17001 started in July 1996 a HAART-regimen
containing the NRTIs zidovudine (AZT) and lamivudine (3TC)
and the protease inhibitor (PI) Ritonavir (RTV) after irregularly
AZT monotherapy. RTV was used irregularly in the first 4
months, and even when RTV treatment was reinitiated the viral
load remained above 10,000 copies/ml. After 90 weeks the
patient was switched to stavudine (d4T), didanosine (ddI) and
Saquinavir (SQV). Two years later the protease inhibitor RTV
was reinitiated. Nevertheless, the HIV-RNA plasma concentra-
tion remained very high and quite stable. After an initial
increase, the CD4 count subsequently decreased over time
(Fig. 1).
RNA isolation and amplification
HIV-1 nucleic acids were isolated essentially according to
the method described by Boom et al. (1990). Briefly, samples
were resuspended in lysis buffer containing silica (NucliSens®,
Organon Teknika, Boxtel, The Netherlands) and incubated for
10 min at room temperature to let the nucleic acids bind to the
silica. The samples were washed twice with washing buffer
(NucliSens), twice with ethanol and once with acetone (Merck)
before the nucleic acids were eluted in 100 μl poly(A) RNA
(40 ng/μl).
The extracted HIV-1 RNA was reverse transcribed and
amplified using a one-tube PCR essentially as described before
(Nijhuis et al., 1995). To amplify the N-terminal part of RT
primers RT18 (5′-GGA AAC CAAAAATGATAGGGGGAA
TTG GAG G-3′; nucleotides 2377–2407) and RT21 (5′-CTG
TAT TTC TGC TAT TAA GTC TTT TGATGG-3′; nucleotides
3539–3510) were used. cDNA synthesis was performed for
30 min at 42 °C, followed by reverse transcriptase inactivation
and DNA denaturation for 5 min at 95 °C. Subsequently 35
cycles of amplification were performed, consisting of a
denaturation step for 1 min at 95 °C, an annealing step for
1 min at 55 °C and an extension step for 2 min at 72 °C,
followed by an elongation step of 10 min at 72 °C. The amount
of amplified product was further amplified in a nested PCR,
using primers RT19 (5′-GGA CATAAA GCTATA GGTACA
G-3′; nucleotides 2454–2475) and RT20 (5′-CTG CCA GTT
CTA GCT CTG CTT C-3′; nucleotides 3462–3441). DNAwas
denatured for 5 min at 95 °C, followed by 30 cycles of 1-min
denaturation at 95 °C, 1-min annealing at 55 °C and 2-min
extension at 72 °C. The amplicons were further elongated for
10 min at 72 °C.
PCR-amplified products were purified using the QIAquick
PCR purification kit (Qiagen, Leusden, The Netherlands).
Sequence analysis
The nested PCR products were genotypically analyzed using
the Big Dye Terminator v1.1 Cycle Sequencing kit (Applied
Biosystems). Purified PCR product (3 μl, if necessary diluted)
was added to 2 μl 5× BigDye sequencer buffer, 4 μl Ready
Reaction premix, 4 μl primer and 7 μl MilliQ. The sequenceprogram consisted of respectively 1 min at 96 °C, followed by
25 cycles of 10 s at 96 °C, 5 s at 50 °C and 4 min at 60 °C. The
N-terminal part of RT was sequenced using primers RT19,
RT20, KRT (5′-CAG GAT GGA GTT CAT AAC-3′, nucleo-
tides 3258–3241), BRT (5′-GGATGG AAA GGATCA CC-3′,
nucleotides 3003–3019) and BRRT (5′-GGT GAT CCT TTC
CAT CC-3′, nucleotides 3019–3003). All sequence reactions
were analyzed on an ABI Prism® 377 DNA Sequencer and
Sequence Navigator 1.0.1 software (Perkin Elmer).
Clonal sequence analysis
Nested PCR products generated with primers RT19 and
RT20 were ligated in the pGEM-T easy vector (Promega)
according to the manufacturer's instructions. Escherichia coli
JM109 High Efficiency Competent Cells (Promega) were used
for transformation. Colonies were picked and cultured over-
night at 37 °C in 5 ml LBmedium supplemented with ampicillin
(40 μg/ml). The plasmid was isolated using the QIAGEN
Plasmid Mini Kit (Qiagen) and PCR amplified using the
primers RT19 and RT20 as described before. Subsequently, the
clones were genotypically analyzed using primers RT19, RT20,
BRT, BRRT and KRT as described previously.
Recombinant virus stocks
The generation of the recombinant virus stocks was per-
formed essentially as described before (Boucher et al., 1996).
The amount of infectious virus in a viral stock (TCID50) in
PBMC was determined by the method of Japour et al. (1993)
and Reed and Muench (1938).
The 184T reference strain was described by Keulen et al.
(1997).
Site-directed mutant
Generation of a site-directed mutant was performed using the
wild type NRT-vector as described previously (Van Maarseveen
et al., 2006). Briefly, recombinant virus was generated by
amplification, digestion and ligation of the N-terminal part of
RT (amino acids 25–314) in an HXB2 wild type backbone.
Primer R70A-RT (5′-TAA TTT TCT CCA TGC ATT ACT-3′,
nucleotides 2771–2751) was used together with primers RT-
BalI (5′-ATG GCC CAA AAG TTA AAC AAT GG-3′; 2599–
2621) and RT-21 to change the second arginine at position 70
into an alanine.
Correct viral clones, determined by sequence analysis, were
transfected in 293T cells to obtain the site-directed mutant virus.
Replication competition experiments
For determination of the relative replication capacity of the
viruses, competition experiments were performed.
Replication competition experiments in PBMC were per-
formed by mixing two recombinant viruses at a ratio of 25:75
and 50:50 based on TCID50. In a total volume of 1 ml, 5×10
6
PHA-stimulated PBMC were infected at a multiplicity of
404 M.C.D.G. Huigen et al. / Virology 364 (2007) 395–406infection (m.o.i.) of 0.0015. After 2 h of infection at 5%CO2 and
37 °C, cells were washed and subsequently cultured in 10 ml
fresh complete culture medium supplemented with 10 U/ml IL-
2. The level of virus production was determined using a HIV-1
p24 antigen ELISA as described. If the amount of p24 exceeded
20 ng/ml, 1 ml virus supernatant was used for infection of fresh
5×106 PHA-stimulated PBMC until 5 passages. RNA was
extracted from culture supernatant at several time points and the
N-terminal part of RTwas amplified and sequenced as described
before. The amount of mutant compared to the original variant in
the population was determined by estimating the relative peak
heights of the electropherograms.
Replication competition experiments in Sup-T1 cells were
performed essentially as described for PBMC. However, 2×106
Sup-T1 cells were infected at an m.o.i. of 0.001 and virus
supernatant was passaged when full-blown syncytia were
present in the culture.
In vitro evolution experiments
In vitro evolution experiments were performed in PBMC
using a recombinant virus clone containing the novel insertion.
At an m.o.i. of 0.001, 5×106 PHA-stimulated PBMC were
infected with this virus clone for 2 h, subsequently washed and
resuspended in 10 ml complete culture medium supplemented
with 10 U/ml IL-2. If necessary, the virus culture was
replenished with fresh culture medium and/or cells. Virus
production was measured by p24 antigen ELISA and 1 ml virus
supernatant was used for infection of fresh 5×106 PHA-
stimulated PBMC when the amount of p24 was higher than
20 ng/ml. At several time points, RNA was extracted from
culture supernatant and the N-terminal part of RT sequenced as
described before (Van Maarseveen et al., 2006).
Drug susceptibility analysis
The susceptibility for several RTIs in PBMC was
determined by infecting PHA-stimulated PBMC at an m.o.i.
of 0.001 in a rotator at 5% CO2 and 37 °C in a total volume of
1 ml. After 2 h, the cells were washed twice and resuspended
in complete culture medium supplemented with 10 U/ml IL-2.
Serial dilutions of the nucleoside analogue were made in
complete culture medium supplemented with IL-2 and added
to the infected cells in triploid. After 7-day incubation at 5%
CO2 and 37 °C, the viral supernatant was inactivated by
Empigen (final concentration of 0.05%; Calbiochem, La Jolla,
CA, USA) and incubation for 30 min at 56 °C. The amount of
virus production was determined using an HIV-1 p24 antigen
ELISA as described before (Moore et al., 1990; McKeating et
al., 1991). Briefly, D7320 (Biochrom) was used as coating
antibody, BC1071-AP (Aalto) as alkaline-phosphatase-con-
jugated monoclonal antibody and the AMPAK™ amplification
system kit (Dako, Cambridgeshire, UK) was used for
detection. Phenotypic resistance was determined by comparing
the 50% inhibitory concentration (IC50) with a wild type
reference strain (HIV-1 HXB2) as described previously
(Boucher et al., 1996).The susceptibility for AZT in MT-2 cells was performed
essentially as described by Boucher et al. (1996).
Replication capacity under drug pressure
To determine the replicative fitness of the viruses under drug
pressure we have infected 2×105 PBMC at an m.o.i. of 0.001 as
described before and incubated the infected cells with a serial
dilution of a nucleoside analogue and measured the level of
virus production after 7 days by a p24 antigen ELISA as
described previously.
Modeling of the 5-residue insert
In order to investigate possible structural effects of the
insertion mutant modeling studies were undertaken. The
KGSNR insert was introduced into the coordinates of the RT-
DNA catalytic complex (Huang et al., 1998) using the
molecular graphics program ‘O’ (Jones et al., 1991). Manual
model rebuilding was initially used to remove clashes and then
minimization carried out by simulated annealing molecular
dynamics in CNS (Brunger et al., 1998).
Estimation of in vivo viral fitness
The establishment of the insertion mutant in the patient was
detected by sequencing 3 clones and 2 mixtures from samples 4
and 5 each (week 233 and 263 after start of HAART): none of
the sequences contained the insertion mutant in the first sample,
and all sequences contained it in the latter. To investigate the
fitness advantage of the 5-amino-acid insertion in vivo, two
samples intermediate of samples 4 and 5; samples 4A and 4B
(weeks 236 and 247 after start of therapy), were used for
extensive clonal sequence analysis. From both samples 20 viral
clones were generated, each containing a unique RT sequence.
We obtained a maximum likelihood estimate for the frequency
of the mutant at each sampling from the observed composition
of the sequenced clones by a Bayesian procedure. The obtained
data series were then used to estimate the relative fitness
advantage of the insertion mutant by the algorithm developed
by Bonhoeffer et al. which considers also the standard deviation
of each point and corrects for fluctuations in the overall virus
load (Bonhoeffer et al., 2002).
Determination of reverse transcriptase activity
To determine the reverse transcriptase activity of multiple
recombinant virus clones, we used the colorimetric reverse
transcriptase kit (Roche Applied Science) according to the
manufacturer's instruction. To correct for the amount of virus in
each stock, 20 ng p24, as determined by a HIV-1 p24 ELISA as
previously described, was used as input in the assay.
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